Hyponatremia: an update on current pharmacotherapy.

about

Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia.Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.Acute liver failure in dogs and cats.

P2860

Q30418165-18186A3C-5D2D-464C-B763-79FD506FCC97 Q38199770-F22880FE-F869-41C4-B345-C6F034440EC4 Q38425134-6E607791-863F-4128-B84B-51BEFCB4874A

P2860

Hyponatremia: an update on current pharmacotherapy.

Item

http://www.wikidata.org/entity/Q38089919

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Hyponatremia: an update on current pharmacotherapy.

@en

type

Item

label

Hyponatremia: an update on current pharmacotherapy.

@en

prefLabel

Hyponatremia: an update on current pharmacotherapy.

@en

P1476

Hyponatremia: an update on current pharmacotherapy.

@en

P2093

Dmitry Shchekochikhin

http://www.w3.org/2001/XMLSchema#string

Oleksandra Tkachenko

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of euvolemic hyponatremia in the intensive care unit by urea

Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

Reversal of transtentorial herniation with hypertonic saline.

Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.

Oral tolvaptan is safe and effective in chronic hyponatremia

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

P304

747-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.781584

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert W Schrier

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23496346

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Hyponatremia: an update on current pharmacotherapy.

about

P2860

P2860

Hyponatremia: an update on current pharmacotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921